Previous studies have analyzed the interrelation between anti-angiogenic dose and efficacy, reporting that low-dose anti-VEGF/VEGFR monoclonal antibodies/VEGFR-2 TKIs are contributed to normalizing the tumor vasculature and inhibiting the growth of new vessels. Here, VEGFA is linked to neoplasm.